8-K: VolitionRx Reports Strong 2025 Revenue Growth, Sepsis Program

VolitionRx Limited announced its full fiscal year 2025 financial results, reporting significant revenue growth and key advancements in its Nu.Q Cancer and Nu.Q NETs assays.

Summary

• Full-year revenue for 2025 was $1.7 million, representing a 40% growth over the previous year.
• Q4 revenue growth was 133% year-over-year.
• Operating expenses for the year were down $4.8 million, or 17%, compared to the previous year.
• Net loss was down 14% for the year versus 2024.
• Net cash used in operating activities was $19.7 million for the year, down 24%.
• Received the first order for Nu.Q Cancer assays for clinical certification ahead of routine clinical use in lung cancer.
• Nu.Q NETs assay was included in a real-world interventional evaluation of early detection of sepsis, in a government-backed program worth approximately $7.3 million in France.
• Engaged in discussions with around 10 of the world's leading diagnostic and liquid biopsy companies for human diagnostics licensing agreements.
• Subsequent to year-end, the company received $5.4 million in net proceeds from equity sales, $1.9 million in net proceeds from issuance of a convertible note and warrant, and $1.0 million of non-dilutive funding from agencies of the Walloon Region, with an additional approximate $0.9 million expected.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update given the strong revenue growth, reduced operating expenses, and significant progress in product commercialization and strategic partnerships, despite the ongoing net loss and going concern warning.

Positives

• Strong Q4 2025 revenue growth of 133% year-over-year.
• Full-year 2025 revenue increased by 40% to $1.7 million.
• Operating expenses decreased by $4.8 million (17%) year-over-year, indicating improved cost management.
• Net loss reduced by 14% compared to 2024.
• Net cash used in operating activities decreased by 24% to $19.7 million, showing better cash flow management.
• Secured the first order for Nu.Q Cancer assays for clinical certification in lung cancer, a significant step towards commercialization.
• Nu.Q NETs assay was included in a substantial $7.3 million government-backed sepsis detection program in France, validating its potential.
• Actively pursuing licensing agreements with approximately 10 leading diagnostic and liquid biopsy companies, indicating strong market interest.
• Successfully raised $8.3 million in net proceeds subsequent to year-end ($5.4M equity, $1.9M convertible note, $1.0M non-dilutive funding), with an additional $0.9 million expected, bolstering liquidity.

Negatives

• The company still reported a net loss for the year, despite a 14% reduction.
• Net cash used in operating activities remains substantial at $19.7 million, indicating ongoing cash burn.
• The audit opinion from the independent registered public accounting firm includes an explanatory paragraph related to the company's ability to continue as a going concern.

Risks

• Failure to develop and commercialize diagnostic, prognostic, or disease monitoring products may prevent the execution of the plan of operations.
• Failure to obtain necessary regulatory clearances or approvals to distribute and market future products.
• Lack of marketplace acceptance for products in the development pipeline or any other diagnostic, prognostic, or disease monitoring products.
• Failure to secure adequate intellectual property protection.
• Fierce competition and potential obsolescence of intended products due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change.
• Downturns in domestic and foreign economies.
• The company's ability to continue as a going concern, as noted in the audit opinion from its independent registered public accounting firm.

Future Outlook

Management anticipates further human licensing deals and expects 2025, the first quarter of 2026, and the next few quarters to be transformational for the company. An additional approximate $0.9 million in non-dilutive funding is expected to be received in tranches based on certain time and event milestones over the next 12 months.

Management Comments

• "We set out over fifteen years ago to help save lives and improve outcomes for millions of patients worldwide, and I could not be prouder of the progress we are making towards that goal." Cameron Reynolds, President and Group Chief Executive Officer.
• "In 2025 we not only received our first order for the Nu.Q Cancer assays for clinical certification ahead of routine clinical use in lung cancer, but we also announced the inclusion of our Nu.Q NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed program (~$7.3 million) in France." Cameron Reynolds.
• "Our tests are about to be used in both these devastating diseases, to help save lives in real world hospital settings: an extremely proud moment for our entire team." Cameron Reynolds.
• "Our goal is to secure a range of licensing agreements in the human diagnostics space and to that end we are in discussions with around 10 of the worlds leading diagnostic and liquid biopsy companies and are at various stages of the process across our different pillars, ranging from due diligence to tech transfer, to evaluation of clinical samples, to contract negotiation." Cameron Reynolds.
• "I believe we will look back on 2025, this first quarter of 2026 and indeed in time, the next few quarters, as transformational for the company." Cameron Reynolds.

Industry Context

StockSavvy.ai notes that VolitionRx's focus on epigenetics for early detection of cancer and sepsis aligns with a growing trend in precision medicine and liquid biopsy, a highly competitive but rapidly expanding market. The inclusion of their Nu.Q NETs assay in a government-backed sepsis program in France highlights the increasing recognition of novel diagnostic tools in critical care, while discussions with leading diagnostic companies indicate potential for significant market penetration through strategic partnerships.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks. However, the reported 40% revenue growth and 17% reduction in operating expenses suggest operational improvements that could be favorable compared to early-stage biotech companies, though the continued net loss and going concern warning indicate the company is still in a high-investment, pre-profitability phase common for innovative diagnostic firms.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth, reduced losses, and progress in commercialization and licensing. However, the "going concern" warning and continued capital raises could introduce dilution risk.
• Patients: Potential for improved outcomes in lung cancer and sepsis detection through the advancement and eventual routine clinical use of Nu.Q Cancer and Nu.Q NETs assays.
• Employees: Positive impact from company growth and progress, potentially leading to job security and expansion.
• Partners/Customers: Strengthened relationships and potential for new collaborations as licensing discussions progress and products move towards clinical use.

Next Steps

• Conference call on April 1, 2026, to discuss results and upcoming milestones.
• Anticipate further human licensing deals in the diagnostics space.
• Expect to update on progress of licensing deals as they are completed.
• Receive an additional approximate $0.9 million in non-dilutive funding over the next 12 months based on milestones.

Key Dates

Recommendation

While VolitionRx demonstrated strong revenue growth, improved financial efficiency, and significant progress in product development and commercialization, the continued net loss and the 'going concern' explanatory paragraph in the audit opinion warrant caution. The successful capital raises provide liquidity, but the long-term viability still depends on securing substantial licensing deals and achieving profitability. A 'hold' recommendation reflects the promising developments balanced against the inherent risks of an early-stage biotech company with ongoing financial challenges.

Keywords

VolitionRx, VNRX, Epigenetics, Nu.Q Cancer, Nu.Q NETs, Sepsis Detection, Cancer Diagnostics, Liquid Biopsy, Financial Results, Biotechnology, Diagnostics, SEC Filing